Can you take Clobazam with Linvoseltamab?

cloBAZam has a major potential interaction with Acute Alcohol Intoxication.

The use of benzodiazepines with alcohol is not recommended. Patients with acute alcohol intoxication exhibit depressed vital signs. The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur. Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.

cloBAZam has a moderate potential interaction with Depression.

Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

cloBAZam has a major potential interaction with Drug Dependence.

Benzodiazepines have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages. However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms. Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines. It may be prudent to refrain from dispensing large quantities of medication to these patients. After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule. If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.

Linvoseltamab has a moderate potential interaction with Immunodeficiency.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

Linvoseltamab has a moderate potential interaction with Infection.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

Linvoseltamab has a moderate potential interaction with Liver Disease.

The effect of moderate to severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal with any AST) on the pharmacokinetics of linvoseltamab is unknown. Due to the risk of hepatotoxicity with linvoseltamab, monitor liver enzymes and bilirubin at baseline and during treatment as indicated.

Linvoseltamab has a moderate potential interaction with Neutropenia.

Linvoseltamab can cause serious, life-threatening, or fatal infections. Neutropenia and febrile neutropenia have been reported with use of linvoseltamab. Assess patients for signs and symptoms of preexisting infection before starting therapy. Evaluate immunoglobulin levels and complete blood cell counts at baseline. Monitor for infection during treatment, especially in patients with neutropenia. Administer prophylactic anti-infectives, vaccines, and immunoglobulin according to clinical guidelines.

cloBAZam has a moderate potential interaction with Psychosis.

Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

cloBAZam has a moderate potential interaction with Renal Dysfunction.

Benzodiazepines are excreted by the kidneys and should be used with caution in patients with impaired renal function and end-stage kidney disease.

Linvoseltamab has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal dysfunction/end-stage renal disease (CrCl 29 mL/min or less) on the pharmacokinetics of linvoseltamab is unknown.